Legend Biotech Corp. · NASDAQ:LEGN
Legend Biotech — Q4 2024 Earnings Presentation
21 slides from Legend Biotech's earnings presentation, Mar 11, 2025
Slide 1: Fourth Quarter 2024 Financial Results & Corporate Update
March 11, 2025 Fourth Quarter 2024 Financial Results & Corporate Update This presentation is for investor relations purposes only - Not for product promotional purposes 1
Slide 2: Forward-looking Statements
Forward-looking Statements This presentation has been prepared by Legend Biotech Corporation (“Legend Biotech” or the unrealized foreign exchange losses in 2026; the progress of such submissions with the FDA, “Company”) solely for information purpose and does not contain all relevant information the
Slide 3: Non-IFRS financial metrics
Non-IFRS financial metrics This presentation refers to certain non-IFRS financial metrics. We use Adjusted Net Loss and Adjusted Net Loss per Share (which we sometimes refer to as “ANI per Share”) as performance metrics. Adjusted Net Loss and ANI per Share are not defined under IFRS, are not a measu
Slide 4: Agenda
1 Opening Remarks 2 Q4 2024 Performance Overview Agenda 3 4 Our Pipeline Upcoming Milestones 5 Financial Performance 6 Q&A 4 This presentation is for investor relations purposes only - Not for product promotional purposes
Slide 5: Presenters
Forward-looking Statements Ying Huang, PhD Jessie Yeung Chief Executive Officer Interim Chief Financial Officer 5 This presentation is for investor relations purposes only - not for product promotional purposes
Slide 6: Proven Leader on the Path to Cure
– Proven Leader on the Path to Cure First and only CAR-T cell therapy demonstrating superior OS vs SoC in Multiple Myeloma >5,000 patients treated worldwide 2nd line launching as we approach blockbuster status Strongest CAR-T launch to date driven by commercial and manufacturing execution Internatio
Slide 7: US and EU CARVYKTI Supply Overview
US and EU CARVYKTI® Supply Overview Facilities Expansion/ Process Optimization UPCOMING MILESTONES • Aim to double commercial supply in 2025 to achieve: • 10,000 annualized doses Tech Lane Facilities Driving Online To Full Capacity exiting 2025 Doses • 20,000 annualized doses Obelisc Clinical exitin
Slide 8: A New Standard for CAR-T Launches
A New Standard for CAR-T Launches CARVYKTI® - INDUSTRY FIRST ELEVEN QUARTERS L E A D I N G E A R LY L A U N C H OUTPERFORMING HISTORICAL PERFORMANCE CAR-T LAUNCHES WOR L DW IDE SAL ES OF CAR-T THERAPIES, BY QUARTER OF LAU NCH (IN $MM) 450 Carvykti Kymriah Yescarta Tecartus Breyanzi Abecma 400 387 35
Slide 9: CARVYKTI Uptake Continues
CARVYKTI® Uptake Continues Continued market penetration, population in earlier lines of treatment represents significant opportunity for continued growth YoY Growth1 QoQ Growth2 CARVYKTI® Net Trade Sales ($MM) U.S. 108% 17% +110% growth vs Q4’23 OUS 138% 15% 400 Global 110% 17% 350 300 31 27 304 → U
Slide 10: Leveraging Most Comprehensive CAR-T Patient Data in Multiple Myeloma
Leveraging Most Comprehensive CAR-T Patient Data in Multiple Myeloma 900+ PATIENTS STUDIED GROWING REAL-WORLD DATA ON IN CLINICAL TRIALS 4,000+ COMMERCIAL PATIENTS 2025 TANDEM MEETINGS: Colorado Blood Cancer Institute (CBCI) and Mayo Clinic Posters 10 This presentation is for investor relations purp
Slide 11: Earlier Line Studies
Earlier Line Studies Another Opportunity to Change the Treatment Paradigm CARTITUDE-21 CARTITUDE-52 CARTITUDE-63 NCT04133636 NCT04923893 NCT05257083 • Global, multi-cohort study • Global, randomized, registrational • Global, randomized, registrational • Phase II open-label study of cilta- study stud
Slide 12: Proven CAR-T Market Leader in MM Forging the Path to Cure
- Proven CAR-T Market Leader in MM Forging the Path to Cure CARVYKTI® Transformed the Multiple Myeloma Treatment Paradigm 2022 2023 2024 2025 2026 4L+ Approval 2L+ Approval Continued Market Leadership Indication Expansion Deepening Community Penetration Preparing for 1L Use New Data Redefining Treat
Slide 13: Our Pipeline
Our Pipeline Global US China Cilta-cel Clinical Studies PHASE 1 PHASE 2 PHASE 3 CARTITUDE-5* CARTITUDE-6* BCMA-directed LEGEND-2† CARTIFAN-1* CARTITUDE-1* CARTITUDE-2* CARTITUDE-4* NDMM NDMM RRMM autologous RRMM RRMM RRMM MM 1-3 Prior Lines Transplant Not Transplant NCT03090659 NCT03758417 NCT035482
Slide 14: Recent and Upcoming Anticipated Milestones
Recent and Upcoming Anticipated Milestones RECENT MILESTONES ANTICIPATED MILESTONES Obtained FDA approval for CARVYKTI® in 2L+ • Continue executing global launches for CARVYKTI® in Establishing a strong relapsed and lenalidomide-refractory MM 2L+ therapy foundation for CARVYKTI® Obtained EMA approva
Slide 15: Q4 2024 Financial Highlights
Q4 2024 Financial Highlights IFRS Total Revenue (in $MM) IFRS Net Income/(Loss) Adjusted Net Loss 1 (in $MM) (in $MM) 200 40 0 20 26 -10 150 0 -20 -20 -30 -59 100 187 -40 -40 -89 -60 -50 50 -80 -145 -60 80 -100 -70 0 -120 -80 -140 -90 Q4 Q4 -160 Q4 Q4 -100 Q4 Q4 2023 2024 2023 2024 2023 2024 IFRS Ne
Slide 16: FY 2024 Financial Highlights
FY 2024 Financial Highlights IFRS Total Revenue (in $MM) IFRS Net Income/(Loss) Adjusted Net Loss 1 (in $MM) (in $MM) 800 0 0 -100 -177 -50 600 -189 -100 -200 -150 400 -518 -336 627 -300 -200 200 -250 285 -400 0 -300 -500 -350 FY FY -600 FY FY -400 FY FY 2023 2024 2023 2024 2023 2024 IFRS Net Income
Slide 17: Investments in Commercialization and Pipeline
Investments in Commercialization and Pipeline 4Q 2024 Operating Expenses ($ MM) Full Year Operating Expenses ($ MM) 200 800 180 20.7 700 160 -1.3 83.3 31.3 600 140 500 120 100 400 187.5 168.1 697.7 80 300 583.1 60 200 40 100 20 0 0 2023 Q4 R&D Delta SG&A Delta 2024 Q4 FY 2023 R&D Delta SG&A Delta FY
Slide 18: Reconciliation of IFRS to Non-IFRS Metrics
Reconciliation of IFRS to Non-IFRS Metrics Three months ended Year ended December 31, December 31, ($ in thousands, except per share data) 2024 2023 2024 2023 Net income/(loss) 26,284 (144,818) (177,026) (518,254) Depreciation and amortization 6,796 5,351 23,359 20,451 Share-based compensation 13,38
Slide 19: Executing Toward Anticipated Company Wide Profitability in 2026
Executing Toward Anticipated Company Wide Profitability in 2026 K E Y D R IVE R S COMMERCIAL MANUFACTURING FINANCIAL Further expand Increasing Scaling business with market leadership in manufacturing ~$1B cash position Multiple Myeloma efficiency CAR-T therapies Continued margin Expanding capacity e
Slide 20: Q&A
Q&A Ying Huang, Ph.D. Jessie Yeung Chief Executive Officer Interim Chief Financial Officer Alan Bash Guowei Fang, Ph.D. Mythili Koneru, M.D., Ph.D. President of CARVYKTI® President of Research Chief Medical Officer and Development 20 This presentation is for investor relations purposes only - Not fo
Slide 21: Thank you!
Thank you! 21 This presentation is for investor relations purposes only - Not for product promotional purposes